566 related articles for article (PubMed ID: 30702997)
21. Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review.
Shanker A; Bhupathi V
Curr Cardiol Rep; 2019 May; 21(7):56. PubMed ID: 31104152
[TBL] [Abstract][Full Text] [Related]
22. Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease.
Welsh RC; Peterson ED; De Caterina R; Bode C; Gersh B; Eikelboom JW
Am Heart J; 2019 Dec; 218():100-109. PubMed ID: 31715433
[TBL] [Abstract][Full Text] [Related]
23. Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
Parascandolo E; Eisen A
Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):577-585. PubMed ID: 32755422
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study.
Lamy A; Eikelboom J; Sheth T; Connolly S; Bosch J; Fox KAA; Zhu J; Lonn E; Dagenais G; Widimsky P; Branch KRH; Bhatt DL; Zheng Z; Straka Z; Dagenais F; Kong Y; Marsden T; Lee SF; Copland I; Yusuf S
J Am Coll Cardiol; 2019 Jan; 73(2):121-130. PubMed ID: 30654882
[TBL] [Abstract][Full Text] [Related]
25. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Windecker S; Tijssen J; Giustino G; Guimarães AH; Mehran R; Valgimigli M; Vranckx P; Welsh RC; Baber U; van Es GA; Wildgoose P; Volkl AA; Zazula A; Thomitzek K; Hemmrich M; Dangas GD
Am Heart J; 2017 Feb; 184():81-87. PubMed ID: 27892890
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic Agents.
Chan NC; Weitz JI
Circ Res; 2019 Feb; 124(3):426-436. PubMed ID: 30702990
[TBL] [Abstract][Full Text] [Related]
27. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both.
Fox KAA; Anand SS; Aboyans V; Cowie MR; Debus ES; Zeymer U; Monje D; Vogtländer K; Lawatscheck R; Gay A
Am Heart J; 2020 Apr; 222():166-173. PubMed ID: 32092505
[TBL] [Abstract][Full Text] [Related]
28. External applicability of the COMPASS trial: the Western Denmark Heart Registry.
Würtz M; Olesen KKW; Thim T; Kristensen SD; Eikelboom JW; Maeng M
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):192-199. PubMed ID: 30916315
[TBL] [Abstract][Full Text] [Related]
29. Antithrombotic Treatments in Patients with Chronic Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomised Controlled Trials.
Bauersachs R; Wu O; Briere JB; Bowrin K; Borkowska K; Jakubowska A; Taieb V; Toumi M; Huelsebeck M
Cardiovasc Ther; 2020; 2020():3057168. PubMed ID: 32695228
[TBL] [Abstract][Full Text] [Related]
30. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
Anand SS; Caron F; Eikelboom JW; Bosch J; Dyal L; Aboyans V; Abola MT; Branch KRH; Keltai K; Bhatt DL; Verhamme P; Fox KAA; Cook-Bruns N; Lanius V; Connolly SJ; Yusuf S
J Am Coll Cardiol; 2018 May; 71(20):2306-2315. PubMed ID: 29540326
[TBL] [Abstract][Full Text] [Related]
31. Antithrombotics in stable peripheral artery disease.
Kaplovitch E; Rannelli L; Anand SS
Vasc Med; 2019 Apr; 24(2):132-140. PubMed ID: 30799766
[TBL] [Abstract][Full Text] [Related]
32. Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Weitz JI; Angiolillo DJ; Geisler T; Heitmeier S
Thromb Haemost; 2020 Aug; 120(8):1147-1158. PubMed ID: 32594508
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
Lee MC; Liao CT; Toh HS; Chou CC; Chang WT; Chen ZC; Wu WS; Yu T; Strong C
Cardiovasc Drugs Ther; 2021 Jun; 35(3):539-547. PubMed ID: 32910340
[TBL] [Abstract][Full Text] [Related]
34. Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
McClure GR; Kaplovitch E; Narula S; Bhagirath VC; Anand SS
Curr Cardiol Rep; 2019 Aug; 21(10):115. PubMed ID: 31471666
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
Rivera-Caravaca JM; Camelo-Castillo A; Ramírez-Macías I; Gil-Pérez P; López-García C; Esteve-Pastor MA; Orenes-Piñero E; Tello-Montoliu A; Marín F
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281167
[TBL] [Abstract][Full Text] [Related]
36. Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
Tsilimigras DI; Moris D; Karaolanis G; Kakkos SK; Filis K; Sigala F
Curr Pharm Des; 2018; 24(38):4516-4517. PubMed ID: 30621559
[TBL] [Abstract][Full Text] [Related]
37. Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS Trial.
Nicholls SJ; Nelson AJ
Am J Cardiovasc Drugs; 2019 Aug; 19(4):343-348. PubMed ID: 30680652
[TBL] [Abstract][Full Text] [Related]
38. Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
Gibler WB
Crit Pathw Cardiol; 2018 Jun; 17(2):53-68. PubMed ID: 29768312
[No Abstract] [Full Text] [Related]
39. Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Shah R; Hellkamp A; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Hacke W; Halperin JL; Hankey GJ; Fox KA; Nessel CC; Mahaffey KW; Piccini JP; Singer DE; Patel MR;
Am Heart J; 2016 Sep; 179():77-86. PubMed ID: 27595682
[TBL] [Abstract][Full Text] [Related]
40. Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
Lapébie FX; Aboyans V; Lacroix P; Constans J; Boulon C; Messas E; Ferrières J; Bongard V; Bura-Rivière A
Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):439-449. PubMed ID: 34330647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
